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https://doi.org/10.1016/j.trsl.2018.0Cerebral cholesterol metabolism is perturbed in late-onset Alzheimer’s disease
(AD), but whether also the extracerebral cholesterol metabolism is perturbed is not
known. Thus, we studied whole-body cholesterol synthesis and absorption with
serum noncholesterol sterols in men without AD (n = 114) or with (n = 18) "pure" AD
(no concomitant atherosclerotic cardiovascular disease) in a long-term cohort (the
Helsinki Businessmen Study) of home-dwelling older men without lipid-lowering
drugs and on their habitual home diet. Serum lipids did not differ between AD and
controls, but age was higher (78 § 1 vs 74 § 0.3 years, mean § standard error,
P < 0.001), age-adjusted plasma glucose concentration was lower (4.8 § 0.3 vs 5.7
§ 0.1 mmol/L, P = 0.011), and APOE e4 allele and frailty were more frequent in AD
than in controls. Of the age and frailty-adjusted serum noncholesterol sterols des-
mosterol and lathosterol ratios to cholesterol reflecting cholesterol synthesis were
lower in AD than in controls (eg, lathosterol 114 § 12 vs 137 § 5 102 mmol/mmol cho-
lesterol, P = 0.004). Cholestanol ratio to cholesterol was higher in AD than in controls
suggesting increased cholesterol absorption. lathosterol/sitosteroll ratio reflecting
cholesterol metabolism was lower in AD than in controls (0.95 § 0.28 vs 1.52 § 0.11
102 mmol/mmol cholesterol, P = 0.027). In AD, plasma glucose correlated negatively
with cholesterol synthesis, whereas in controls the correlation was positive. In con-
clusion, extracerebral cholesterol metabolism was altered in AD. This finding along
with the low plasma glucose concentration and its paradoxical interaction with
cholesterol synthesis opens new perspectives in the regulation of cholesterol
metabolism and glucose homeostasis in AD. (Translational Research 2018;
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Sittiwet C, et al.Background
In vitro and animal studies suggest that the culprit
of Alzheimer’s disease (AD) amyloid beta is able
to interfere with cholesterol metabolism. Thus,
we studied extracerebral cholesterol metabolism
in subjects with late-onset AD.
Translational Significance
Cholesterol synthesis and cholesterol metabolism
were downregulated and cholesterol absorption
was increased in AD. Plasma glucose was low in
AD, and its association with cholesterol synthesis
was paradoxical to controls. These findings open
new perspectives to basic research to reveal the
regulation of cholesterol metabolism and glucose
homeostasis in AD thus helping to understand the
development of AD.INTRODUCTION
Late-onset Alzheimer’s disease (AD) is a common
type of dementia in advanced age. The main changes
in AD are extensive deposition of amyloid beta (Ab)
peptide, a cleavage product of amyloid precursor pro-
tein (APP). The deposition of Ab triggers numerous
processes leading to neuronal loss and impairment of
memory and cognition.1 In old age, the development of
AD is a multifactorial process where aging and the
presence of apoprotein E (APOE) e4 allele are well-
known risk factors.1 Brain tissue is rich in cholesterol,
which is completely derived from in situ biosynthesis.2
During the past decades there is increasing evidence
that cholesterol metabolism in brain is involved in the
development of AD.3-5 For example, APOE has a
strong isoform-related effect on cholesterol homeosta-
sis in the brain as well as on the metabolism of Ab.
Cerebral cholesterol synthesis has been assessed with
biomarkers, and in one of the three studies available
cholesterol synthesis was unaffected,6 but in 2 studies
it was lower in AD than in the control subjects.7,8 In 2
of these studies, 24S-hydroxycholesterol was lower in
AD than in controls suggesting that also cholesterol
elimination from brain was decreased in AD.6,7
Accordingly, cerebral cholesterol metabolism is con-
ceivably perturbed in AD.
It is generally considered that plasma cholesterol
concentration does not interact with the cerebral cho-
lesterol if the blood-brain barrier is intact.9 However,
APOE isoforms affect cholesterol metabolism alsoextracerebrally, so that subjects with APOE e4 allele
have lower cholesterol synthesis and higher cholesterol
absorption efficiency than subjects having the APOE
e3 or APOE e2 alleles.10 Cholesterol synthesis alone
without information on cholesterol absorption or cho-
lesterol metabolism has been evaluated in AD in four
studies with controversial results.11-14 The interpreta-
tions are, however, complicated by the fact that in gen-
eral the type of dementia is usually not well defined
and diagnosis of AD in an older individual may
be mixed with varying degrees of vascular disease. We
aimed to control this in the long-term follow-up of the
Helsinki Businessmen Study (HBS).15,16 In this cohort
the cardiovascular risk factors, cognition, morbidity,
and mortality has been followed up from midlife to old
age.15,16 In Finland the diagnosis of AD is generally
based on the criteria presented in Diagnostic and Statis-
tical Manual of Mental Disorders, fourth edition, and
by the National Institute of Neurological Disorders and
Stroke-Alzheimer Disease and Related Disorders
working group.17,18 The diagnosis is clinical, routinely
associated with brain imaging, and made by a clinical
specialist, a neurologist or a geriatrician.16 In this
cohort we pragmatically separated men with AD diag-
nosis into “pure” AD—without any diagnosis of con-
comitant atherosclerotic cardiovascular disease (CVD)
(coronary heart disease, cerebrovascular disease, or
peripheral vascular disease)—and into a mixed demen-
tia with a concomitant diagnosis of any atherosclerotic
cardiovascular disease.16 As a further indication
that “pure” AD defined accordingly indeed was differ-
ent from dementia associated with CVD we noticed
that midlife serum cholesterol concentration predicted
mixed dementia, not “pure” AD, which paradoxically
tended to be associated with lower midlife glucose.16
To this end, the aim of this study was to evaluate
whether extracerebral cholesterol metabolism differs
in men without AD or with late-onset "pure" AD in a
long-term cohort of home-dwelling older men of the
HBS study.MATERIALS AND METHODS
Study population. The HBS cohort has been described
earlier in detail.15,16 In short, initially a healthy cohort
of 3490 executives and businessmen born in
19191934 participated in health check-ups during the
1960s and early 1970s at the Institute of Occupational
Health in Helsinki. They have been followed up since
then with questionnaires and clinical and laboratory
examinations at the University of Helsinki as a clini-
cal-epidemiologic longitudinal cohort. In 2003, a ran-
dom sample of home-dwelling men of the cohort
Translational Research
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medical examination with weight, height, and waist
circumference measurements, body mass index (BMI)
calculation, Mini-mental state examination (MMSE) to
evaluate cognition (maximum 30 points, <24 taken to
denote cognitive impairment),19 frailty was evaluated
using modified frailty phenotype,20 and blood samples
were drawn and analyzed to assess overall health and
to examine serum and lipoprotein lipids and serum
noncholesterol sterols.
The men were followed up to January 2014 with ques-
tionnaires, national registries, and death certificates for
diagnosis of dementia.16 During the follow-up, 20 men,
3% of the 2003 cohort, had received a clinical diagnosis of
"pure" AD. The classification of "pure" ADwas performed
by a neurologist and a geriatrician from our research team
based on the information from questionnaires, health
check-ups, national registers, and the information and nar-
ratives from clinical records and death certificates. If the
available information included no hints of cardiovascular
disease, after mutual consensus the diagnosis of "pure"
AD was settled.16 Those subjects with dementia combined
with signs of CVD (mixed dementia) were not included in
this study. As a control group we included 153 men who
were home-dwelling in 2014 and did not have any signs of
cognitive disorders at an average age of 85 years. Two AD
and 39 control men were taking lipid-lowering drugs in
2003, so that the final study population consisted of 18 AD
and 114 control men.
All subjects gave their written informed consent.
The study was performed according to the principles of
the Declaration of Helsinki. The Ethics Committee of
the Department of Medicine, University of Helsinki
(Revised protocol Dnro 246/E5/2002) has approved
the study follow-up of the HBS cohort.
Methods and measurements. Plasma glucose, serum
uric acid, high sensitive C-reactive protein (hs-CRP),
and serum glutamyltransferase (GT) concentrations
were analyzed with standardized methods at the Central
Laboratory of Helsinki University Hospital. Serum total,
low density lipoprotein and high density lipoprotein
cholesterol and serum triglyceride concentrations were
analyzed enzymatically using automated analyzers of
our hospital laboratory. APOE genotypes were deter-
mined with the polymerase chain reaction method.
Serum cholesterol and noncholesterol sterols D8-
cholestenol (5a-cholest-8-en-3b-ol), desmosterol, lath-
osterol, campesterol, sitosterol, and cholestanol were
analyzed using gas-liquid chromatography (GLC) with
flame ionization detection (FID) and a 50-m capillary
column (Ultra 2, Agilent Technologies, Wilmington,
DE) with 5a-cholestane as internal standard.21 The
samples were extracted with chloroform-methanol,
saponified with potassium hydroxide in ethanol andsilylated with trichloromethylsilane prior to GLC anal-
ysis. In GLC the mobile phase is gas (pure helium),
and a liquid stationery phase is deposited on the inner
wall of a long capillary colon. The separation of cho-
lesterol and noncholesterol sterols in serum depends on
their retention time. When this analysis was developed
in our research laboratory the quantification and char-
acterization of the sterols were checked with mass
spectrometry and using commercial pure sterol stand-
ards. It turned out as it is also generally considered
today that GLC with FID detection is reliable and it
has a good peak resolution when analyzing serum cho-
lesterol and the 6 noncholesterol sterols described
above.21 However, the detection is not sufficient
enough to analyze the serum oxysterols 24S-hydroxys-
terol and 27-hydroxysterol. Serum noncholesterol ster-
ols were expressed as ratios to cholesterol by adjusting
the concentrations with the cholesterol value of the
same GLC run. Ratios to cholesterol of the serum cho-
lesterol precursors (D8-cholestenol, desmosterol, and
lathosterol) reflect cholesterol synthesis, while those of
plant sterols (campesterol and sitosterol) and cholesta-
nol reflect cholesterol absorption efficiency.22-24 We
also calculated the lathosterol/sitosterol ratio, which
reflects whole-body cholesterol metabolism,23,24 and
the lathosterol/desmosterol ratio reflecting the activity
of the 2 different pathways of cholesterol synthesis.
Statistical analysis. Statistical analyses were con-
ducted using SPSS version 22. According to power
analysis based on previous data11 to detect a significant
difference in serum lathosterol to cholesterol ratio
between AD vs controls with an a level of 0.05 (two
sided) and statistical power of 0.80, the required mini-
mal study population should be 46. Normality and
homogeneity of variance assumptions were checked
before further analyses. Univariate analysis of covari-
ance was used to compare the values between the
groups. Variables not normally distributed even after
logarithmic transformation, nonhomogenous in vari-
ance, or noncontinuous were tested with Mann-Whit-
ney U test or Fisher’s exact test. Spearman correlation
coefficients were calculated. A P value of <0.05 was
considered statistically significant. The results are
given as mean § standard error.RESULTS
Table 1 summarizes the key characteristics of the men with “pure”
AD and the controls without any signs of cognitive decline. The
mean age was 77.7 years (range 70-84 years) in the AD and 74.1 years
(range 69-84 years) in the control group (P<0.001), so that all further
analyses were performed with age as a covariate. Frailty was more
prevalent in the AD than in the control group, so that frailty was also
taken as a covariate in all analyses. The range of BMI varied from 19
to 31 kg/m2 in both groups, and the mean values of BMI and waist
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Volume 202 Sittiwet et al 123circumference were similar between the groups. Mean plasma glu-
cose was significantly lower in the AD compared with the control
group, but serum uric acid, hs-CRP, and GT concentrations did not
differ between the groups and were within the reference values. Half
of the AD men had at least one APOE e4 allele compared to 25% in
the control men (P<0.05). MMSE was different between the groups,
but also in the AD group 85% had at least 24 points, which is the con-
ventional cutoff of cognitive decline. This indicates that clinical AD
was mainly developed after the health check-up in 2003; in fact the
clinical diagnosis of AD had been set during the following 3 to
10 years (mean 7.8 years) after 2003. Alcohol consumption and
smoking did not differ between the groups.
Hypertension had been diagnosed in 52% of the men with AD and
in 39% of the controls, and the difference was not significant between
the groups (Table 1). None of the men with AD had a history of
major CVD (coronary heart disease, cerebrovascular disease, or
peripheral vascular disease) or type 2 diabetes, whereas in the control
group 14% had a positive history of atherosclerotic vascular disease
and 7% had type 2 diabetes (Table 1). The prevalence of these dis-
eases was, however, not significant between the groups, neither was
the prevalence of the history of cancer, which had been treated and
was in remission.
Serum and lipoprotein cholesterol and serum triglyceride concen-
trations did not differ between the groups (Table 2). The range of
serum cholesterol varied from 3.6 to 6.9 mmol/l in the AD and from
3 to 7.5 mmol/l in the control group.
After adjustment for age and frailty, serum desmosterol and lath-
osterol ratios to cholesterol were significantly lower in the AD than
in the control group (Table 2). Lathosterol/desmosterol ratio did not
differ between the groups. Regarding cholesterol absorption markers,
serum cholestanol ratio to cholesterol was higher in the AD than in
the control group. Lathosterol/sitosterol ratio, marker of cholesterol
metabolism, was lower in the AD than in the control group. Serum
plant sterols did not significantly differ between the groups.
In both groups, the cholesterol synthesis markers were interrelated
depicted for serum lathosterol and desmosterol in Fig 1, panel A.
Likewise, cholesterol absorption markers were interrelated shown for
serum cholestanol and sitosterol in Fig 1, panel B. In the AD and con-
trol groups, cholesterol homeostasis was intact shown for the inverse
interrelation between serum lathosterol and sitosterol in Fig 2.
Plasma glucose correlated positively with serum D8-cholestenol in
the control group but negatively in the AD group (Fig 3). Frailty was
not associated with age, BMI, MMSE, plasma glucose, hs-CRP,
APOE isoforms, serum or lipoprotein lipids or serum noncholesterol
sterols in either of the groups.DISCUSSION
The new observations in the present study were that
in men with late-onset "pure" AD—dementia diagnosis
without signs of concomitant clinical atherosclerosis—
the extracerebral cholesterol synthesis and cholesterol
metabolism were downregulated compared with the
control men. The synthesis markers, serum desmos-
terol and lathosterol ratios to cholesterol, were
5%18% lower and the lathosterol/sitosterol ratio was
37% lower in the AD compared with the control group.
Cholesterol synthesis was downregulated within its
both pathways, that is, in the Bloch unsaturated and the
Kandutsch-Russell saturated side chain pathway. One
of the surrogate markers of cholesterol absorption
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124 Sittiwet et al December 2018efficiency, cholestanol to cholesterol ratio, was
increased by 6% suggesting that cholesterol absorption
efficiency was upregulated. The serum noncholesterol
sterol to cholesterol ratios, validated biomarkers in sev-
eral different non-AD populations22-30 proved to reflect
cholesterol metabolism also in AD.
We have demonstrated earlier in a large cohort of the
HBS population that lower midlife glucose was associ-
ated with "pure" AD.16 Also in this study plasma glu-
cose concentration was lower in the AD than in the
control group. Although diabetes is usually considered
an AD risk factor, this may not be the case if AD
pathology is verified and vascular contribution
excluded.31-33 Another unexpected finding related to
plasma glucose was that in AD plasma glucose concen-
tration correlated negatively with cholesterol synthesis
and not positively as expected.34 This paradoxical find-
ing opens new perspectives to find out whether the reg-
ulation between cholesterol metabolism and glucose
homeostasis is perturbed in AD.
AD was developed during the following 310 years
after the present health check-up in 2003. As expected,
higher age and the presence of APOE e4 allele charac-
terized the development of AD. Frailty was also more
frequent in the AD than in the control group already in
2003. On the contrary, the frequency of the most preva-
lent diseases, smoking habits, alcohol consumption, or
the rest of the clinical variables including hs-CRP, GT,
and uric acid did not seem to interfere with the devel-
opment of AD. The mean BMI value was normal in
both groups, and none of the subjects in either of the
groups had below normal BMI.
In older subjects with AD, extracerebral cholesterol
synthesis has earlier been evaluated in four studies.11-
14 In three of these studies, the possibility of vascular
dementia had been screened by brain imaging.11,12,14
In three studies serum lathosterol or desmosterol ratio
to cholesterol was lower in the AD than in the control
group,11-13 but in one study no difference could be
observed between the groups.14 Thus, the present study
confirmed the downregulated cholesterol synthesis in
AD but also demonstrated reduced whole-body choles-
terol metabolism and a slight increase in cholesterol
absorption efficiency. We have demonstrated earlier
that old age without AD interferes with cholesterol
metabolism, so that in 75-year-old men cholesterol
absorption efficiency, bile acid synthesis, and biliary
cholesterol excretion were diminished compared with
50-year-old men, but cholesterol synthesis was pre-
served at the same level in old age as in middle-age.35
Accordingly, AD seems to have a different impact on
cholesterol metabolism than aging alone.
What are the possible mechanisms interfering with
cholesterol metabolism in AD? APOE e4 isoform
Fig 1. Correlation of (A) serum lathosterol to desmosterol and (B) cholestanol to sitosterol in the control men
and in men with Alzheimer’s disease (AD).
Translational Research
Volume 202 Sittiwet et al 125decreases cholesterol synthesis and serum lathosterol
to cholesterol ratio10 similarly as observed in the pres-
ent study making it a possible factor. Frailty, the other
variable frequent in AD is characterized by reduced
physiological reserves and increased vulnerability, but
the exact biological processes causing this syndrome
are mainly unknown. In this study frailty did not corre-
late with any of the clinical or metabolic variables.
According to these results, it seems unlikely that frailty
has any impact on cholesterol metabolism in AD.
In vitro and in animal studies the cleavage products
of APP are able to regulate cholesterol homeostasis.36
The b- cleavage product of APP, Ab, was able to
downregulate the key regulator of cholesterolsynthesis, sterol regulatory element-binding protein 2
(SREBP 2) in astrocytes and hepatic cells resulting in
decreased cholesterol synthesis and low density lipo-
protein receptor content in these cells. Moreover, in
human studies two subjects with an autosomal domi-
nant form of early-onset familial AD caused by a dupli-
cation of the APP gene (APPDpD11X X) in combination with
increased b-cleavage, serum precursors (squalene, lath-
osterol, and desmosterol ratios to cholesterol) were
reduced suggesting that Ab conceivably regulates cho-
lesterol synthesis also in human subjects.36 The surro-
gates of cholesterol absorption efficiency remained
within reference values. The ability of Ab peptide to
downregulate SREBP 2 may also explain the novel
Fig 2. Correlation of serum lathosterol to sitosterol in the control men and in men with Alzheimer’s disease
(AD).
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plasma glucose concentration with cholesterol synthe-
sis observed in non-AD populations31 was turned nega-
tive in the AD subjects.
The study has both limitations and strengths. First,
the study population consisted only of men of highest
social strata with late-onset AD so that the results areFig 3. Correlation of plasma glucose to serum D8-cholesten
r = 0.265, P = 0.011) and in men with Alzheimer’s disea
P = 0.002).not extendable to other AD populations. The number
of men developing AD in this cohort was also smaller
than expected, only 20 out of 651 men (3%). However,
the size of the study population exceeded the demand
of the power calculation. Second, the serum noncholes-
terol sterols could not be validated with the absolute
measurements of cholesterol metabolism, because theyol in the control men (open circles, continuous line,
se (AD) (closed circles, broken line, r = -0.757,
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Volume 202 Sittiwet et al 127are too complex and demanding to be used in the AD
population. The assessment of validity of the serum
biomarkers had to be based on the information that
cholesterol homeostasis was intact and that the synthe-
sis markers as well as the absorption markers were
interrelated. Today, the noncholesterol sterols are
widely used in sterol research relying on the earlier
results of validation in different non-AD populations.
Finally, the strengths of this study are the socio-
economically homogenous population and the aim
to "purify" the AD diagnosis from vascular compo-
nents. For the latter, an obvious limitation is that
diagnosis of AD was not made personally by the
present study team. However, in Finland dementia
diagnosis is generally made by specialists in a struc-
turized fashion including brain imaging, and for
each man the study team checked carefully the clin-
ical history from the HBS longitudinal data, patient
records, drug reimbursement registers, and narra-
tives and diagnoses of death certificates.16 None of
the men with AD had a history of major atheroscle-
rotic CVD (coronary heart disease, cerebrovascular
disease, or peripheral vascular disease). In addition,
hypertension was not more prevalent in AD com-
pared with controls, and midlife cholesterol pre-
dicted mixed dementia but not AD.16 Although it is
not guaranteed that our definition of "pure" AD is
devoid of any vascular component, we believe that
reducing the atherosclerotic burden from the AD
diagnosis nevertheless can better reveal the real bio-
logic processes involved in AD.
In conclusion, the novel findings were that choles-
terol synthesis and cholesterol metabolism were lower
whereas cholesterol absorption was higher in the AD
compared with the control subjects. Plasma glucose
concentration was low in AD, and its association with
cholesterol synthesis was paradoxical to controls.
These findings open new perspectives in the regulation
of cholesterol metabolism and glucose homeostasis in
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